Fruquintinib
| CAS No. | 1194506-26-7 | Cat. No. | BCP15692 |
| Name | Fruquintinib | ||
| Synonyms | HMPL-013;HMPL013;HMPL 013; | ||
| Formula | C21H19N3O5 | M. Wt | 393.39 |
| Description | Fruquintinib, also known as HMPL-013, is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | VEGFR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.